Eli Lilly stock undercut its 50-day line on Jan. 14 after cutting its fourth-quarter and 2024 outlook. Is LLY stock a sell ...

The Vatican said that Thursday’s fall also occurred at Santa Marta, and the pope was later seen in audiences with his right ...

As the Biden presidency winds down, the administration touted its Cancer Moonshot accomplishments, including regulatory action against forever chemicals and ethylene oxide, expanded access to cancer ...

Lilly is considering expanding the availability of lower-priced vials of its blockbuster obesity drug Zepbound ...

Eli Lilly and Company LLY announced that the FDA has granted approval to its drug, Omvoh (mirikizumab), for its second ...

Hard-core floaters swear by the health benefits. The Dallas Cowboys were early adopters. In a blue-lit room at Altered States ...

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...

Pope Francis fell Thursday and hurt his arm, the Vatican said, just weeks after another apparent fall resulted in a bad ...

When Penn Cambria School District classes end for the 2024-25 academic year, it will be the last time students will walk the ...

BofA Securities analysts reaffirmed a Buy rating for Eli Lilly (NYSE:LLY) with a price target on the stock of $997. The company stands out as a premier opportunity within the large-cap biopharma ...

Berenberg analyst Kerry Holford lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,050 and keeps a Buy rating on the shares.

Eli Lilly has received approval from the US Food and Drug Administration (FDA) for Omvoh (mirikizumab-mrkz) to treat ...